All In Biotech

NDA 202324 · Pf Prism Cv

Inlyta

Axitinib · Oral · Kinase Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jul 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jan 27, 2012

Approved uses

3

Original approval plus efficacy supplements

Registered trials

209

20 Phase 3, 29 recruiting

FAERS reports

19,549

12,971 serious, 3,948 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 15, 2026.

Axitinib is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) 1.1 First-Line Advanced Renal Cell Carcinoma Axitinib in combination with avelumab is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC). Axitinib in combination with pembrolizumab is indicated for the first-line treatment of patients with advanced RCC. 1.2 Second-Line Advanced Renal Cell Carcinoma Axitinib as a single agent is indicated for the treatment of advanced RCC after failure of one prior systemic therapy.

Mechanism: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGF-mediated endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft mouse models.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 22, 2022 Supplement 14 · Efficacy LabelLetter
  • Jun 4, 2020 Supplement 11 · Efficacy · priority review LabelLetter
  • Jan 27, 2012 Original approval · Type 1 - New Molecular Entity NovelReviewLetterLabel
2 products under this application
  • INLYTA · AXITINIB 1MG · TABLET, ORAL · Prescription · TE AB
  • INLYTA · AXITINIB 5MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Axitinib" as an intervention, any sponsor and status, largest first.

All 209 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death2,699
  • diarrhoea2,594
  • fatigue2,123
  • hypertension1,331
  • neoplasm progression1,324
  • disease progression1,211
  • off label use1,207
  • nausea1,145
  • decreased appetite1,094
  • dysphonia1,013
  • blood pressure increased855
  • weight decreased806

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
200918
201032
201128
2012569
20131,060
20141,157
20151,094
2016814
2017766
2018697
20191,160
20202,413
20212,270
20222,688
20231,907
20241,429
2025889
2026557

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Inlyta (Axitinib)

2024 spending

$439M

Beneficiaries

4,465

24,770 claims

Per beneficiary

$98,299

$238.19 per unit

View as table
YearSpending
2020$263,233,497
2021$376,064,185
2022$417,577,746
2023$466,771,314
2024$438,904,956

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 285 on PubMed

Sponsor: Pf Prism Cv

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.